直接抗病毒藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、按適應症、按途徑、按配銷通路、按地區和競爭細分，2020-2030 年

2024 年全球直接抗病毒藥物市場價值為 114.1 億美元，預計到 2030 年將達到 236.1 億美元，複合年成長率為 12.86%。由於病毒感染（尤其是C型肝炎）的盛行率不斷上升，全球直接抗病毒 (DAA) 藥物市場正在擴大。這些藥物針對特定的病毒蛋白來抑制複製，提供了一種高效且耐受性良好的治療選擇。製藥業的進步促進了下一代 DAA 的開發，其療效更高、治療時間更短。隨著醫療保健提供者和政府優先考慮丙型肝炎消除計劃，市場正在經歷顯著成長。聯合療法的引入進一步增強了治療效果，降低了抗藥性風險並提高了持續病毒學反應（SVR）率。擴大發展中國家獲得診斷檢測和治療的機會在市場擴張中發揮著至關重要的作用。

在政府措施和非營利組織的支持下，人們對早期診斷和治療的認知不斷提高，市場也因此受益。對抗病毒藥物研究的投入不斷增加，促進了安全性更高的創新療法的開發。個人化醫療的轉變正在影響對有針對性的抗病毒療法的需求，確保更高的治療成功率。生物技術和基因研究的突破使製藥公司能夠設計出更精確、更有效的 DAA。與注射治療相比，口服療法的受歡迎程度日益提高，這推動了患者的依從性，使 DAA 成為抗病毒治療策略的首選。研究機構和製藥公司之間的合作正在加速藥物開發，從而形成強大的下一代 DAA 管道。各國不斷擴大的醫療基礎設施和優惠的報銷政策正在為市場參與者創造機會。

儘管取得了進步，但市場仍面臨著治療成本高昂的挑戰，限制了低收入地區患者的治療可及性。抗藥性病毒株的出現越來越令人擔憂，需要不斷研究以開發更有效的配方。新的 DAA 的監管障礙和漫長的核准流程可能會延遲進入市場，影響創新週期。某些地區對有效抗病毒治療的認知有限，導致採用率降低。學名藥的出現加劇了市場競爭，給定價策略帶來了壓力。透過策略定價模型、抗藥性管理研究和擴大全球治療範圍來應對這些挑戰對於維持市場成長至關重要。

主要市場促進因素

高效且提高治癒率

主要市場挑戰

治療費用高昂

主要市場趨勢

擴大適應症

目錄

第 1 章：產品概述

第 2 章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球直接抗病毒藥物市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依類型（NS3/4A 蛋白酶、NS5A 蛋白質、NS5B RNA 依賴性 RNA 聚合酶）
  • 依適應症（C型肝炎病毒、HIV感染/愛滋病、流感、預防）
  • 依途徑（靜脈注射、口服、皮下注射、外用）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 產品市場圖
  • 依藥物類型
  • 按適應症
  • 按路線
  • 按配銷通路
  • 按地區

第6章：北美直接抗病毒藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第7章：歐洲直接抗病毒藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 法國
  • 義大利
  • 西班牙

第 8 章：亞太直接抗病毒藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 日本
  • 印度
  • 澳洲
  • 韓國

第9章：南美洲直接抗病毒藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲直接抗病毒藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 合併與收購
• 產品發布

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• 納特科製藥股份有限公司
• Vertex 製藥公司
• 雷迪博士實驗室有限公司
• 強生公司
• 默克公司
• 吉利德科學公司
• 艾伯維公司
• 百時美施貴寶公司

第 15 章：策略建議

第16章調查會社について,免責事項

Global Direct-acting Antiviral Drug Market was valued at USD 11.41 Billion in 2024 and is expected to reach USD 23.61 Billion in the forecast period with a CAGR of 12.86% through 2030. The global direct-acting antiviral (DAA) drug market is expanding due to the increasing prevalence of viral infections, particularly hepatitis C. These drugs target specific viral proteins to inhibit replication, offering a highly effective and well-tolerated treatment option. Pharmaceutical advancements have led to the development of next-generation DAAs with improved efficacy and shorter treatment durations. The market is witnessing significant growth as healthcare providers and governments prioritize hepatitis C elimination programs. The introduction of combination therapies has further enhanced treatment outcomes, reducing the risk of drug resistance and increasing sustained virologic response (SVR) rates. Expanding access to diagnostic testing and treatment in developing countries is playing a crucial role in market expansion.

The market is benefiting from increasing awareness of early diagnosis and treatment, supported by government initiatives and non-profit organizations. Rising investments in antiviral drug research are fostering the development of innovative therapies with improved safety profiles. The shift toward personalized medicine is influencing the demand for targeted antiviral therapies, ensuring higher treatment success rates. Breakthroughs in biotechnology and genetic research are enabling pharmaceutical companies to design more precise and potent DAAs. The growing preference for oral therapies over injectable treatments is driving patient adherence, making DAAs a preferred choice in antiviral treatment strategies. Collaborations between research institutions and pharmaceutical firms are expediting drug development, leading to a robust pipeline of next-generation DAAs. Expanding healthcare infrastructure and favorable reimbursement policies in various countries are creating opportunities for market players.

Despite advancements, the market faces challenges related to high treatment costs, limiting accessibility for patients in low-income regions. The emergence of drug-resistant viral strains is a growing concern, requiring continuous research to develop more effective formulations. Regulatory hurdles and lengthy approval processes for new DAAs can delay market entry, impacting innovation cycles. Limited awareness in certain regions about the availability of effective antiviral treatments is slowing adoption rates. The presence of generic alternatives is intensifying market competition, putting pressure on pricing strategies. Addressing these challenges through strategic pricing models, research in resistance management, and increased global treatment outreach will be essential for sustaining market growth.

Key Market Drivers

High Efficacy and Improved Cure Rates

In recent years, the global pharmaceutical landscape has witnessed a transformative shift in the treatment of viral infections, particularly hepatitis C, due to the advent of direct-acting antiviral drugs (DAAs). These innovative medications have demonstrated exceptional efficacy, with cure rates exceeding 95%, redefining the approach to managing viral diseases.

The high efficacy of DAAs translates into significantly improved patient outcomes. For instance, a study published in JAMA Network Open reported that among patients treated with DAAs, 97.3% achieved sustained virologic response (SVR), indicating a cure. Successful DAA therapy not only clears the virus but also halts disease progression, reducing risks of liver fibrosis, cirrhosis, and hepatocellular carcinoma.

Beyond individual benefits, DAAs contribute to public health by reducing viral transmission. Effective treatment decreases viral load, thereby lowering the likelihood of spreading infections such as hepatitis B and C, which are transmitted through routes like blood contact and sexual intercourse. The World Health Organization highlights that DAAs can cure over 95% of hepatitis C cases, yet access to diagnosis and treatment remains limited globally.

DAAs also offer shorter treatment durations compared to traditional interferon-based therapies. While older regimens required treatment courses of up to 48 weeks, DAA therapies typically range from 8 to 12 weeks, enhancing patient compliance and reducing healthcare burdens. Furthermore, DAAs are associated with improved tolerability and fewer severe side effects, encouraging patients to complete their treatment regimens.

The success of DAAs has instilled confidence among patients and healthcare providers. For example, the U.S. Department of Health and Human Services notes that new hepatitis C treatments can cure approximately 95% of patients, significantly decreasing the likelihood of severe liver complications and reducing overall healthcare costs. This underscores the importance of expanding access to these life-saving therapies to achieve broader public health benefits.

Key Market Challenges

High Treatment Costs

One of the most significant challenges is the high cost of direct-acting antiviral drugs. While these medications are highly effective, their price tags can be prohibitive for many patients, especially in low- and middle-income countries. Striking a balance between recouping research and development costs and ensuring affordable access is a persistent challenge.

Key Market Trends

Expanded Indications

One significant trend in the DAA market is the exploration of expanded indications. While DAAs have been predominantly used to treat hepatitis C and B, researchers are investigating their efficacy against other viral infections. This could lead to the development of new DAA therapies targeting a broader range of viruses.

Key Market Players

• Natco Pharma Ltd
• Vertex Pharmaceuticals Inc
• Dr Reddy's Laboratories Ltd
• Johnson & Johnson
• Merck & Co Inc
• Gilead Sciences Inc
• AbbVie Inc
• Bristol-Myers Squibb Co

Report Scope:

In this report, the Global Direct-acting Antiviral Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Direct-acting Antiviral Drug Market, By Type:

• NS3/4A Protease
• NS5A Protein
• NS5B RNA-Dependent RNA polymerase

Direct-acting Antiviral Drug Market, By Indication:

• Hepatitis C Virus
• HIV Infection/ AIDS
• Influenza
• Prophylaxis

Direct-acting Antiviral Drug Market, By Route:

• Intravenous
• Oral
• Subcutaneous
• Topical

Direct-acting Antiviral Drug Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Direct-acting Antiviral Drug Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Direct-acting Antiviral Drug Market.

Available Customizations:

Global Direct-acting Antiviral Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Direct-acting Antiviral Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 5.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 5.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Drug Type
  • 5.3.2. By Indication
  • 5.3.3. By Route
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North America Direct-acting Antiviral Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 6.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 6.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Direct-acting Antiviral Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Route
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Direct-acting Antiviral Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Route
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Direct-acting Antiviral Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Route
      • 6.3.3.2.4. By Distribution Channel

7. Europe Direct-acting Antiviral Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 7.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 7.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 7.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Direct-acting Antiviral Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Route
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. United Kingdom Direct-acting Antiviral Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Route
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. France Direct-acting Antiviral Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Route
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Direct-acting Antiviral Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Route
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Direct-acting Antiviral Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Route
      • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Direct-acting Antiviral Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 8.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 8.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 8.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Direct-acting Antiviral Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Route
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Japan Direct-acting Antiviral Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Route
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. India Direct-acting Antiviral Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Route
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. Australia Direct-acting Antiviral Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Route
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. South Korea Direct-acting Antiviral Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Route
      • 8.3.5.2.4. By Distribution Channel

9. South America Direct-acting Antiviral Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 9.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 9.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 9.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Direct-acting Antiviral Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Route
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Direct-acting Antiviral Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Route
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Direct-acting Antiviral Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Route
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Direct-acting Antiviral Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 10.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 10.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 10.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Direct-acting Antiviral Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Route
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Direct-acting Antiviral Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Route
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Direct-acting Antiviral Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Route
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.6.1. Natco Pharma Ltd
• 14.6.2. Vertex Pharmaceuticals Inc
• 14.6.3. Dr Reddy's Laboratories Ltd
• 14.6.4. Johnson & Johnson
• 14.6.5. Merck & Co Inc
• 14.6.6. Gilead Sciences Inc
• 14.6.7. AbbVie Inc
• 14.6.8. Bristol-Myers Squibb Co

15. Strategic Recommendations

16. About Us & Disclaimer